Study of risk factors in patient with persistent elevation of liver enzymes after treatment of chronic HCV by Direct acting antiviral drugs

Abstract

Chronic hepatitis C is a viral liver disease characterized by a variable degree of liver inflammation and liver fibrosis. In addition chronic hepatitis C virus (HCV) infection may be present in patients with concomitant non-viral liver disease . Manns MP,(2017) The introduction of oral direct-acting antivirals (DAAds) has modified the prognosis of hepatitis C, since HCV eradication occurs in most treated patients with the achievement of sustained virological response 12 weeks after completion of treatment (SVR12), reduces patients’ risks for cirrhosis, diminishes extrahepatic manifestations and is associated with fibrosis regression. Singh S,(2018) This allows the reassessment of risk factors associated with liver damage after elimination of HCV, which may be reflected by either persistently elevated ALT or lack of ALT reduction following viral eradication fatty liver, due to metabolic syndrome has gained attention as considerable and enduring comorbidity after SVR with DAAds Olveira A,(2018) The aim of this study is to determine risk factors that cause persistent elevation of liver enzymes in hepatitis c virus patients treated by direct acting antiviral drugs (dyslipidemia, high BMI, type2 diabte, NAFLD).